- Home
- ACLX vs FHI Comparison
ACLX vs FHI Comparison
Compare ACLX & FHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- FHI
- Stock Information
- Founded
- ACLX 2015
- FHI 1955
- Country
- ACLX United States
- FHI United States
- Employees
- ACLX N/A
- FHI N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- FHI Investment Managers
- Sector
- ACLX Health Care
- FHI Finance
- Exchange
- ACLX Nasdaq
- FHI Nasdaq
- Market Cap
- ACLX 3.5B
- FHI 3.4B
- IPO Year
- ACLX 2022
- FHI N/A
- Fundamental
- Price
- ACLX $67.16
- FHI $45.54
- Analyst Decision
- ACLX Strong Buy
- FHI Hold
- Analyst Count
- ACLX 14
- FHI 6
- Target Price
- ACLX $111.42
- FHI $42.33
- AVG Volume (30 Days)
- ACLX 567.9K
- FHI 803.2K
- Earning Date
- ACLX 08-07-2025
- FHI 07-24-2025
- Dividend Yield
- ACLX N/A
- FHI 2.99%
- EPS Growth
- ACLX N/A
- FHI 2.09
- EPS
- ACLX N/A
- FHI 3.58
- Revenue
- ACLX $76,809,000.00
- FHI $1,659,262,000.00
- Revenue This Year
- ACLX N/A
- FHI $5.57
- Revenue Next Year
- ACLX $112.68
- FHI $3.48
- P/E Ratio
- ACLX N/A
- FHI $12.71
- Revenue Growth
- ACLX N/A
- FHI 2.19
- 52 Week Low
- ACLX $47.86
- FHI $31.94
- 52 Week High
- ACLX $107.37
- FHI $45.62
- Technical
- Relative Strength Index (RSI)
- ACLX 59.84
- FHI 74.42
- Support Level
- ACLX $63.13
- FHI $41.96
- Resistance Level
- ACLX $67.83
- FHI $43.75
- Average True Range (ATR)
- ACLX 2.52
- FHI 0.72
- MACD
- ACLX 0.14
- FHI 0.24
- Stochastic Oscillator
- ACLX 90.30
- FHI 97.95
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About FHI Federated Hermes Inc.
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $800 billion in managed assets at the end of September 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (74%) funds. The firm's cash-management operations are expected to generate around 51% of Federated's revenue this year, compared with 29%, 12%, and 7%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (65% of AUM), institutional investors (26%), and international clients (9%).